| Literature DB >> 29541481 |
Roseanne O Yeung1,2,3, Jing-Heng Cai4, Yuying Zhang2,3, Andrea O Luk2, Jun-Hao Pan4, Junmei Yin2,3, Risa Ozaki2,3, Alice P S Kong2,3, Ronald Ma2,3, Wing-Yee So2,3, Chiu Chi Tsang5, K P Lau6, Edwin Fisher7, Williams Goggins2, Brian Oldenburg8, Julianna Chan2,3.
Abstract
BACKGROUND: In a randomized controlled trial of 628 Chinese patients with type 2 diabetes receiving multidisciplinary care in the Joint Asia Diabetes Evaluation (JADE) Progam, 372 were randomized to receive additional telephone-based peer support (Peer Empowerment And Remote communication Linked by information technology, PEARL) intervention. After 12 months, all-cause hospitalization was reduced by half in the PEARL group especially in those with high Depression Anxiety and Stress Scale (DASS) scores.Entities:
Keywords: Adherence; Hospitalizations; Integrated care; Negative emotions; Peer support; Quality improvement; Structural equation modelling
Year: 2018 PMID: 29541481 PMCID: PMC5842642 DOI: 10.1186/s40842-018-0055-6
Source DB: PubMed Journal: Clin Diabetes Endocrinol ISSN: 2055-8260
Fig. 1Proposed structural equation model with hypothesized explanatory and outcome variables (rectangle: measured variables; oval: latent variables) and interlinking paths to explain the multi-causality of hospitalization (15). Abbreviations: PEARL: peer support intervention, Frequency: number of hospitalization episodes, Stay: Length of hospital stay, PHQ-9: 9-item Patient Health Questionnaire assessing depressive symptoms, DASS-21: 21-item Depression Anxiety Stress Scale, CDDS-15: 15-item Chinese Diabetes Distress Scale, Medication Adherence: 4-item Morisky Medication Adherence Scale, CKD: Chronic Kidney Disease with eGFR 15–60 ml/min/1.73 m2, CVD: Cardiovascular disease including coronary heart disease (myocardial infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation), stroke, peripheral vascular disease (lower extremity amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization), BP: Blood pressure, SBP (systolic) DBP (diastolic), TC/LDL-C: Total cholesterol/LDL-cholesterol, TG: Triglycerides, BMI: Body mass index, Waist: waist circumference, N.B. Baseline explanatory measures were analyzed
Clinical, biochemical, psychological and behavioural parameters stratified by hospitalization and baseline DASS-21 score
| Hospital admission | Baseline DASS-21 score | |||||
|---|---|---|---|---|---|---|
| No ( | Yes ( | < 17 ( | ≥17 ( | |||
| Age, years | 54·1 ± 9·4 | 56·7 ± 8·6 | 0·003 | 54·9 ± 9·1 | 54·0 ± 9·7 | 0·358 |
| Male, n(%) | 274 (56·6) | 81 (56·3) | 0·939 | 295 (58·6) | 59 (47·6) | 0·026 |
| Diabetes duration, years | 9·1 ± 7·7 | 10·3 ± 7·8 | 0·122 | 9·4 ± 7·7 | 9·5 ± 8·0 | 0·845 |
| Education | ||||||
| < 6 years | 165 (34·1) | 63 (43·8) | 0·079 | 171 (34·0) | 57 (46·0) | 0·005 |
| 6–11 years | 247 (51·0) | 62 (43·1) | 252 (50·1) | 56 (45·2) | ||
| > 11 years | 72 (14·9) | 19 (13·2) | 80 (15·9) | 11 (8·9) | ||
| Complications | ||||||
| Chronic kidney disease | 25 (5·2) | 21 (14·8) | < 0·001 | 34 (6·8) | 12 (9·8) | 0·251 |
| Diabetic retinopathy | 166 (34·3) | 56 (38·9) | 0·312 | 169 (33·6) | 53 (42·7) | 0·057 |
| All heart events | 41 (8·5) | 26 (18·3) | 0·001 | 52 (10·4) | 15 (12·1) | 0·586 |
| JADE Risk categories | ||||||
| Very high risk | 73 (15·1) | 36 (25·0) | 0·003 | 86 (17·1) | 23 (18·5) | 0·474 |
| High risk | 385 (79·5) | 104 (72·2) | 391 (77·7) | 97 (78·2) | ||
| Medium risk | 24 (5·0) | 4 (2·8) | 24 (4·8) | 4 (3·2) | ||
| Low risk | 2 (0·4) | 0 (0·0) | 2 (0·4) | 0 (0·0) | ||
| Treatments | ||||||
| Insulin | 165 (34·1) | 54 (37·5) | 0·451 | 174 (34·6) | 45 (36·3) | 0·722 |
| Oral anti-diabetic drugs | 407 (84·1) | 127 (88·2) | 0·226 | 423 (84·1) | 110 (88·7) | 0·197 |
| On BP drugs | 305 (63·0) | 104 (72·2) | 0·042 | 327 (65·0) | 81 (65·3) | 0·948 |
| On lipid lowering drugs | 194 (40·1) | 84 (58·3) | < 0·001 | 218 (43·3) | 59 (47·6) | 0·394 |
| Risk factors control | ||||||
| Body mass index, kg/m2 | 26·8 ± 4·3 | 27·1 ± 5·0 | 0·563 | 26·6 ± 4·3 | 27·8 ± 4·8 | 0·009 |
| Systolic blood pressure, mmHg | 135·6 ± 18·2 | 136·4 ± 20·9 | 0·633 | 136·2 ± 18·4 | 134·2 ± 20·7 | 0·307 |
| Diastolic blood pressure, mmHg | 80·2 ± 10·5 | 79·0 ± 11·2 | 0·227 | 80·3 ± 10·5 | 78·6 ± 11·5 | 0·115 |
| Hemoglobin A1c, % (mmol/mol) | 8.2 ± 1.6 (66.0 ± 17.9) | 8.2 ± 1.6 (65.7 ± 17.7) | 0.867 | 8.2 ± 1.6 (65.6 ± 17.7) | 8.3 ± 1.7 (67.2 ± 18.7) | 0.394 |
| Total cholesterol, mmol/L | 4·91 ± 1·07 | 4·71 ± 1·06 | 0·044 | 4·83 ± 1·07 | 4·99 ± 1·08 | 0·160 |
| Triglyceride, mmol/L | 1·40 (1·00–2·00) | 1·49 (1·00–1·97) | 0·704 | 1·40 (1·00–1·97) | 1·52 (1·00–2·30) | 0·076 |
| HDL-C, mmol/L | 1·20 ± 0·36 | 1·23 ± 0·36 | 0·433 | 1·21 ± 0·35 | 1·17 ± 0·37 | 0·265 |
| LDL-C, mmol/L | 2·92 ± 0·78 | 2·77 ± 0·91 | 0·046 | 2·86 ± 0·79 | 2·99 ± 0·91 | 0·131 |
| Estimated GFR, ml/min/1·73m2 | 111·9 ± 33·1 | 102·6 ± 36·8 | 0·005 | 110·2 ± 33·7 | 107·7 ± 36·1 | 0·471 |
| Microalbuminuria | 127 (26·6) | 39 (27·5) | 0·843 | 134 (27·0) | 31 (25·6) | 0·765 |
| Psychological assessment | ||||||
| PHQ-9 score | 4·1 ± 4·1 | 4·7 ± 4·2 | 0·131 | 3·1 ± 3·1 | 8·6 ± 4·9 | < 0·001 |
| CDDS-15 score | 36·8 ± 13·5 | 37·0 ± 12·2 | 0·849 | 34·8 ± 12·8 | 45·1 ± 11·6 | < 0·001 |
| DASS-21 score | ||||||
| Total | 9·3 ± 10·0 | 14·0 ± 14·0 | < 0·001 | 5·9 ± 4·7 | 28·7 ± 11·3 | < 0·001 |
| DASS-depression | 2.75 ± 3.80 | 4.23 ± 5.02 | 0.001 | 1.53 ± 1.85 | 9.48 ± 4.78 | < 0·001 |
| DASS-anxiety | 2.71 ± 3.12 | 4.20 ± 4.63 | < 0·001 | 1.76 ± 1.65 | 8.33 ± 4.39 | < 0·001 |
| DASS-stress | 3.79 ± 3.97 | 5.24 ± 5.02 | 0.002 | 2.55 ± 2.47 | 10.59 ± 4.01 | < 0·001 |
| Medication adherence | ||||||
| High | 200 (43·8) | 65 (47·8) | 0·248 | 225 (47·3) | 40 (34·5) | 0·021 |
| Intermediate | 228 (49·9) | 66 (48·5) | 225 (47·3) | 68 (58·6) | ||
| Low | 29 (6·3) | 5 (3·7) | 26 (5·5) | 8 (6·9) | ||
Definitions of risk categories
1. Very High-Risk group with clinically evident cardiovascular-renal complications
2. High-Risk group with ≥3 stratification parameters and/or values above the high specificity cut off for any one of the risk scores and/or eGFR< 60 ml/min/1.73 m2
3. Medium Risk group with two stratification parameters and values above the high sensitivity cut off but lower than the high specificity cut off for any of the risk scores and eGFR between 60-90 ml/min/1.73 m2 and
4. Low-Risk group with one or fewer stratification parameter and values below the high sensitivity cut off for all risk scores and eGFR≥90 ml/min/1.73 m2
Definitions of complications and risk parameters:
Chronic kidney disease (CKD): estimated glomerular filtration rate 15–60 ml/min per 1.73 m2
Cardiovascular complication: coronary heart disease (myocardial infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation), stroke, peripheral vascular disease (lower extremity amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization)
Renal complications: End stage renal disease (ESRD) requiring dialysis and/or eGFR< 15 ml/min/1.73m2
Microalbuminuria: urinary albumin:creatinine ratio (ACR): ≥2.5 mg/mmol (men) and 3.5 mg/mmol (women)
Macroalbuminuria: urinary ACR > 25 mg/mmol
Retinopathy (typical retinal changes including vitrectomy, haemorrhages, and exudates)
Medication adherence: measured by 4-item Morisky Medication Adherence Scale where 4 is regarded as high adherence, score 2–3 as intermediate adherence, and 0–1 as low adherence
Fig. 2Kaplan Meier curves showing the cumulative proportions of people with type 2 diabetes requiring hospitalization. a Stratified by assignment to peer support (PEARL). b Stratified by baseline negative emotions (DASS≥17). c Stratified by peer support and baseline negative emotions. Pearl denotes peer support intervention. Depression Anxiety Stress Scale are denoted as DASS, using ≥17 points as the cut off for those in the top quintile of subjects with negative emotions
Fig. 3A structural equation model (SEM) showing the effects of change in negative emotions (DASS, PHQ9, CDDS) on hospitalizations (admission episodes and stay) and medication adherence as well as the interaction between peer support and CKD/CVD on hospitalizations. Goodness of fit indices of the model: pvalue of the Chi-squared test is 0.1330; the root mean square error of approximation is 0.019, the CFI value is 0.978. The figure represents the estimates of latent variable relationships to outcome variables with pvalues in parentheses (refer to Table 2 for full details of the SEM). Abbreviations: PHQ-9: 9-item Patient Health Questionnaire assessing depressive symptoms, DASS-21: 21-item Depression Anxiety Stress Scale, CDDS-15: 15-item Chinese Diabetes Distress Scale, Medication Adherence: 4-item Morisky Medication Adherence Scale, CKD: Chronic Kidney Disease as estimated glomerular filtration rate 15–60 ml/min/1.73 m , CVD: Cardiovascular disease including coronary heart disease (myocardial infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation), stroke, peripheral vascular disease (lower extremity amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization)
Summary of the estimated coefficients of the measurement and structural equation
| Measurement equation | |||
| Latent variable | Indicators | Est. ( | Standard Error |
| Change in negative emotions | CDDS | 1.000 (ref) | NA (ref) |
| PHQ-9 | 0.874 (< 0.001) | 0.137 | |
| DASS-21 | 1.390 (< 0.001) | 0.273 | |
| Hospitalisation | Length of stay | 1.000 (ref) | NA (ref) |
| Frequency of hospitalisation | 1.745 (< 0.001) | 0.098 | |
| Structural equation | |||
| Dependent (outcome) variable | Independent (explanatory) Variable | Est. ( | Standard Error |
| Hospitalisation | Change in negative emotions | −0.218 (0.001) | 0.065 |
| Medication adherence | 0.005 (0.833) | 0.022 | |
| Age | 0.013 (0.552) | 0.022 | |
| Peer support | −0.026 (0.576) | 0.046 | |
| CKD | 0.065 (0.580) | 0.118 | |
| Heart disease | −0.001 (0.993) | 0.101 | |
| Peer support×CKD | 0.833 (< 0.001) | 0.171 | |
| Peer support× Heart disease | 0.455 (0.001) | 0.141 | |
| Medication adherence | Change in negative emotions | 0.240 (0.034) | 0.113 |
| Change in negative emotions | Gender | −0.022 (0.684) | 0.054 |
| Education | 0.031 (0.316) | 0.031 | |
| Peer Support | 0.039 (0.471) | 0.053 | |
Goodness of fit indices of the model: p-value of the Chi-squared test is 0.1330; the root mean square error of approximation is 0.019, the CFI value is 0.978
CKD Chronic kidney disease defined by eGFR< 60 ml/min/1.73m2 or dialysis-dependence. Heart disease defined by a history of myocardial infarction, percutaneous coronary intervention, and heart failure